Understanding Monoclonal Mast Cell Activation Syndrome (MMAS)
At a Glance
MMAS is a clonal mast cell disorder caused by an acquired change, often KIT D816V. It can cause severe reactions even when baseline tryptase and blood testing are normal, so diagnosis may require sensitive testing and specialist follow-up.
Receiving a diagnosis of Monoclonal Mast Cell Activation Syndrome (MMAS) often comes after a long and confusing “diagnostic odyssey.” Because the symptoms can mimic many other conditions and the necessary tests are highly specialized, patients often spend years seeking answers for unpredictable, severe reactions [1][2].
MMAS is a clonal mast cell disorder. This means it is caused by a specific “clone” or group of mast cells that carry an acquired genetic mutation (a somatic mutation, not one you inherited), making them behave abnormally [3]. While it is related to other mast cell diseases, it occupies a unique place in the medical world: you have the genetic markers of a clonal mast cell disease, but you do not meet the full criteria for Systemic Mastocytosis (SM) [4].
Clarifying the Terminology
To understand MMAS, it helps to see where it fits among three similar-sounding conditions:
- Secondary MCAS: You have symptoms of mast cell activation caused by an identifiable external trigger, like a classic IgE-mediated allergy.
- Idiopathic MCAS: You have symptoms of mast cell activation, but doctors cannot find a genetic mutation (clonality) or an external allergy causing it [5].
- Monoclonal MCAS (MMAS): You have both the documented symptoms of activation and evidence of a “clone” (like a KIT mutation), but you do not fulfill the diagnostic criteria for Systemic Mastocytosis [4][1].
- Systemic Mastocytosis (SM): This is a diagnosis where mast cells form dense clusters (aggregates) in the bone marrow and/or meet specific “minor criteria” [6]. SM includes indolent (slow-growing) and advanced forms.
In short, MMAS is a primary mast cell disorder where the cells are genetically altered, but the overall “burden” or number of these cells is usually lower than what is seen in SM [7].
The Biological Driver: KIT D816V and Mutations
The behavior of your mast cells is often associated with a specific somatic mutation called KIT D816V. In healthy people, the KIT receptor carefully regulates cell survival and mediator release. In MMAS, the KIT D816V mutation alters this signaling, affecting mast cell survival, proliferation, and phenotype [4][8].
Doctors may also look for “aberrant markers” on the surface of your mast cells, such as CD25 or CD2. These are proteins that shouldn’t normally be there; their presence is a clue that the mast cells belong to a clonal population [9][10].
The Challenge of Diagnosis
Diagnosing MMAS is complex because the mutated cells can be very “low-burden,” meaning they are few and far between.
- High-Sensitivity Testing: Standard genetic tests often miss the mutation if it is only present in a tiny fraction of cells. Specialized high-sensitivity assays (like digital droplet PCR, or ddPCR) are often required to find the mutation [11].
- Blood vs. Marrow: The mutation is much easier to find in the bone marrow than in the blood. In many cases of MMAS, a blood test will come back negative even when the bone marrow is positive [7].
- Tryptase Levels: While a high baseline tryptase (a protein released by mast cells) can be a clue, many people with MMAS have a normal baseline tryptase level [12]. The more important clinical finding is often how much the tryptase rises during a reaction—specifically if it increases by more than 20% plus 2 ng/mL over your normal baseline [8][13].
MMAS and Severe Reactions
MMAS is frequently identified in patients who experience severe, unexplained anaphylaxis (life-threatening allergic reactions), particularly after insect stings.
A critical feature of clonal mast cell disorders like MMAS is that reactions may not look “typical.” Instead of hives, itching, or swelling, a reaction might primarily involve a sudden, dangerous drop in blood pressure (hypotension) or fainting (syncope) [12][14]. Because there are often no visible skin signs, these reactions can be easily misunderstood by emergency responders or doctors unfamiliar with mast cell disorders.
Navigating Your Care
Because MMAS is a rare and specialized diagnosis, your care is best managed by a multidisciplinary team. This usually includes an Allergist/Immunologist to manage reactions and a Hematologist (a blood specialist) to monitor the clonal nature of the cells [1][15].
While MMAS can remain stable for many patients, it requires individualized long-term monitoring of your tryptase levels and symptoms. Identifying the “clonality” is an empowering step—it confirms that your symptoms have a clear biological cause and allows your doctors to tailor your treatment and emergency plans specifically for you [16].
Common questions in this guide
What is monoclonal mast cell activation syndrome?
How is MMAS different from systemic mastocytosis?
What tests are used to diagnose MMAS?
Can a normal tryptase level or negative blood test rule out MMAS?
What can a severe MMAS reaction look like?
Which specialists manage monoclonal mast cell activation syndrome?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Condition differences
Could you explain how MMAS differs from Systemic Mastocytosis?
Genetic testing
Would testing for the KIT D816V mutation be useful in my situation?
Testing options
Is a bone marrow biopsy something we should discuss to look for the mutation?
Get notified when new evidence is published on Monoclonal mast cell activation syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
[Mast cell activation syndrome. About a clinical case].
Cardona R, Muñoz-Ávila MA, Gómez-Henao C, et al.
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2019; (66(4)):504-509 doi:10.29262/ram.v66i4.587.
PMID: 32105433 - 2
The Role of KIT Mutations in Anaphylaxis.
Coulson E, Zhou S, Akin C
Current allergy and asthma reports 2019; (19(6)):31 doi:10.1007/s11882-019-0863-5.
PMID: 31028494 - 3
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI, García-Montero AC, Orfao A, Álvarez-Twose I
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (127(4)):427-434 doi:10.1016/j.anai.2021.07.014.
PMID: 34298172 - 4
Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified.
Ballul T, Sabato V, Valent P, et al.
EClinicalMedicine 2025; (80()):103043 doi:10.1016/j.eclinm.2024.103043.
PMID: 39877259 - 5
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
Valent P, Akin C, Nedoszytko B, et al.
International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239030.
PMID: 33261124 - 6
Systemic Mastocytosis: Molecular Pathophysiology, WHO Diagnostic Framework, and KIT-Directed Targeted Therapies.
Alati C, Greve MB, Porto G, et al.
Cancers 2026; (18(14)) doi:10.3390/cancers18142205.
PMID: 42512272 - 7
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P, Álvarez-Twose I, Pérez-Pons A, et al.
Allergy 2023; (78(5)):1347-1359 doi:10.1111/all.15584.
PMID: 36385619 - 8
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
Matito A, Escribese MM, Longo N, et al.
Journal of investigational allergology & clinical immunology 2021; (31(6)):461-470 doi:10.18176/jiaci.0675.
PMID: 33541851 - 9
Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.
Conde-Fernandes I, Sampaio R, Moreno F, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2017; (13()):21 doi:10.1186/s13223-017-0193-x.
PMID: 28439288 - 10
Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.
Van den Poel B, Kochuyt AM, Del Biondo E, et al.
Acta clinica Belgica 2017; (72(2)):123-129 doi:10.1080/17843286.2017.1293312.
PMID: 28262030 - 11
High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: The reference laboratory perspective.
Shean RC, Hellwig S, Saadalla A, et al.
American journal of clinical pathology 2025; (164(2)):145-149 doi:10.1093/ajcp/aqaf008.
PMID: 40036308 - 12
Hymenoptera Allergy and Mast Cell Activation Syndromes.
Bonadonna P, Bonifacio M, Lombardo C, Zanotti R
Current allergy and asthma reports 2016; (16(1)):5 doi:10.1007/s11882-015-0582-5.
PMID: 26714690 - 13
Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.
Lee E, Picard M
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):49 doi:10.1186/s13223-025-00998-9.
PMID: 41272881 - 14
Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder.
Bonadonna P, Scaffidi L
Immunology and allergy clinics of North America 2018; (38(3)):455-468 doi:10.1016/j.iac.2018.04.010.
PMID: 30007463 - 15
Systemic Mastocytosis: Multidisciplinary Approach.
Zanotti R, Tanasi I, Crosera L, et al.
Mediterranean journal of hematology and infectious diseases 2021; (13(1)):e2021068 doi:10.4084/MJHID.2021.068.
PMID: 34804442 - 16
Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis.
Nöldeke P, Schmalz O, Kvasnicka H, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):40 doi:10.1186/s13223-025-00986-z.
PMID: 40963125
This page explains MMAS, its testing, and severe reaction risks for informational purposes only and does not constitute medical advice. Discuss your results, monitoring, and emergency plan with an allergist, immunologist, or hematologist.